Casdin Capital, LLC Editas Medicine, Inc. Transaction History

Casdin Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$19.49 - $32.63 $8.09 Million - $13.5 Million	-415,000 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$22.49 - $26.81 $1.46 Million - $1.74 Million	-65,000 Reduced 13.54%	415,000 $9.44 Billion
Q4 2018 Feb 13, 2019	BUY	$18.19 - $31.79 $363,800 - $635,800	20,000 Added 4.35%	480,000 $10.9 Million
Q3 2018 Nov 14, 2018	BUY	$27.65 - $38.39 $7.79 Million - $10.8 Million	281,667 Added 157.94%	460,000 $14.6 Million
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $1.41 Million - $1.85 Million	45,000 Added 33.75%	178,333 $6.39 Million
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $2.11 Million - $3.2 Million	133,333	133,333 $3.2 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $92.1M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.